Rybelsus isan oral tablet developedby Novo Nordisk to control blood sugar levels in individuals with type 2 diabetes. This medication was approved by the Food and Drug Administration in 2019 for the U.S. market, and it is also available in other markets such as the European Union, Canada, a...